Five major 2026 sepsis/septic shock trials, summarized in full CCR (Critical Care Reviews) 11-part format. All data extracted verbatim from primary sources — no estimated or rounded figures.
Verdict | Trial | Journal | Takeaway |
⚪ | JAMA Netw Open | Albumin targeting ≥3.0 g/dL: 90d mortality 43.3% vs 45.9%, underpowered. | |
🟢 | Lancet Respir Med | Polymyxin B haemoadsorption (Bayesian): 28d mortality 39% vs 45%, 95.3% posterior probability. | |
🟡 | Lancet Respir Med | Stewardship missed, but mortality cut 16.6%→13.6% (P=0.0009) via unclear mechanism. | |
🟢 | World J Crit Care Med | Sped lactate clearance (5.73h vs 8.54h, P<0.001); underpowered for mortality. | |
⚪ | NEJM | Balanced fluid vs saline in pediatric shock: MAKE30 identical (3.4% vs 3.0%). |